Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis

Speaker(s)

Hu K1, Wang Q1, Yang J1, Tan M1, Zhang B2, Dou G2, Chen Y3, Chen W4, Zhu W1, Kuang Y1
1Xiangya Hospital of Central South University, Changsha, China, 2Lilly Suzhou Pharmaceutical Co., Ltd, Shanghai, China, 3Changsha Normin Health Technology Ltd, Changsha, China, 4Normin Health Consulting Ltd, Mississauga, ON, Canada

OBJECTIVE: To describe the disease characteristics in Chinese adult patients with psoriasis receiving interleukin-17A (IL-17A) inhibitors in a tertiary care clinic in Changsha, China.

METHOD: The prescriptions of patients visiting a Chinese tertiary care clinic for psoriasis from May 2019 to September 2021 were collected to identify psoriasis patients receiving IL-17A inhibitors. We reviewed the medical records of the patients to collect demographics, social economic status, lifestyle, disease severity index, treatment history, and comorbidities. The patient characteristics were summarized using descriptive statistic methods (mean and standard deviation for continuous variables and percentage for categorical variables).

RESULTS: 335 patients (35.2% receiving Ixekizumab and 64.8% receiving Secukinumab) were included for data analysis. The average age, psoriasis onset age, male proportion, body mass index, and body weight of the included patients were 41.0±13.8 years, 30.1±14.2 years, 68.1%, 24.2±4.0 kg/m2, and 68.1±14.2 kg respectively. 45.6% of the included patients had smoking history and 80.5% of the patients had a monthly income of less than ¥6,000. Among the included patients, psoriasis vulgaris (82.1%) was the main psoriasis type; the proportions of mild, moderate, and severe psoriasis were 9.4%, 25.2%, and 65.4% respectively. Psoriasis Area and Severity Index, Body Surface Area, Dermatology Life Quality Index, and Physician Global Assessment were 12.6±8.3, 20.6%±17.8%, 7.7±5.7, and 3.5±1.0 respectively. The main skin lesion sites included scalp (50.8%), lower limbs (23.4%), and body trunk (13.1%). The previous treatments included Chinese traditional medicine (49.6%), chemical immunosuppressants (36.7%), tretinoin (29.0%), biologics drugs (9.3%), and/or phototherapy (9.3%). The main comorbidity was metabolic syndrome (30.4%). The abnormal C-reactive protein and erythrocyte sedimentation rate in these patients were 11.0% and 21.1%, respectively.

CONCLUSION: Chinese psoriasis patients receiving IL-17A inhibitors in real-world setting mainly had moderate to severe disease and had no previous biologic treatments.

Code

RWD142

Disease

Biologics and Biosimilars, Systemic Disorders/Conditions